Cancer Stem Cells can go it Alone
News Jun 12, 2007
At the heart of most, if not all cancers, lie a handful of wayward stem cells that feed the ever growing tumor mass, but their scarcity make it difficult for scientists to study them. Now, times of plenty may lie ahead as a breast cancer cell line – established long ago – turned out to behave a lot like cancer stem cells.
In a study to be published in this week’s online edition of the Proceedings of the National Academy of Sciences an international group of researchers led by Nobel Laureate Renato Dulbecco, M.D., a distinguished research professor and president emeritus of the Salk Institute, demonstrates that injection of a single cell taken from cultured LA7 cells into mouse breast tissue can seed a new mammary carcinoma.
Their finding supports the observation that although cancer stem cells are rare, in the bulk of a tumor, a single cancer stem cell is sufficient to initiate and maintain a malignant tumor.
“We can use single cancer stem cells to study the dynamics and behavior of cancer stem cells and their role in solid tumor formation at the single cell level,” says lead author Ileana Zucchi, Ph.D., a molecular cancer biologist at the Institute for Biological Technology (ITB-CNR) in Milan, Italy.
Having a model cancer stem cell system will also allow researchers to identify genes and proteins that will help with the search for human breast cancer stem cells in the future.
“As we learn more about tumor formation at the single cell level in tissue, we may be able to specifically target cancer stem cells for destruction while leaving the normal stem cells in the body intact,” hopes Zucchi.
The fact that tumor cells and stem cells share many properties has been known for quite some time. The ability of adult stem cells or cancer stem cells to divide and generate both new stem cells (called self-renewal) as well as specialized cell types (called differentiation) is the key to maintaining healthy tissues, and to keep tumors growing indefinitely in the case of cancer stem cells.
When grown in culture dishes, LA7 cells act just like normal stem cells and, when prodded with appropriate cues, differentiate into all the cell lineages found in the mammary gland. Given enough time, the cells form complex, three-dimensional structures resembling the milk-producing alveoli and ducts in normal breast tissue and start to produce milk proteins.
To assess the cells’ tumorigenic potential, the researchers injected the cells into the breast tissue of female mice. Unable to respond to conditions that prevent normal stem cells from spinning out of control, even a single LA7 cell started to form tumors.
“If tumor induction was dependent on injecting more than one cell, it would be difficult to determine whether cells that appear to be resistant to these conditions are simply cell types different from cancer stem cells,” Zucchi says. “But since we start with a single cancer stem cell for injection, we know that the resistance must derive from the original cancer stem cell.”
Researchers from the ITB-CNR in Milan, Italy, the Istituto dei Tumori Genova, Italy, and the Max Planck Institute in Munster, Germany, contributed to this study. The work was supported in part by grants from the Fondazione CARIPLO, Italy.
Scientists have used machine learning to train computers to see parts of the cell the human eye cannot easily distinguish. Using 3D images of fluorescently labeled cells, the research team taught computers to find structures inside living cells without fluorescent labels, using only black and white images generated by an inexpensive technique known as brightfield microscopy.READ MORE
The National Institutes of Health announced the launch of a new initiative to help speed the development of cures for sickle cell disease. The Cure Sickle Cell Initiative will take advantage of the latest genetic discoveries and technological advances to move the most promising genetic-based curative therapies safely into clinical trials within five to 10 years.